Knight Therapeutics Full Year 2023 Earnings: Misses Expectations
Knight Therapeutics (TSE:GUD) Full Year 2023 Results
Key Financial Results
Revenue: CA$328.2m (up 12% from FY 2022).
Net loss: CA$16.8m (loss narrowed by 44% from FY 2022).
CA$0.16 loss per share (improved from CA$0.26 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Knight Therapeutics Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) was also behind analyst expectations.
Looking ahead, revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company's shares are down 1.7% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. See our latest analysis on Knight Therapeutics' balance sheet health.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
